Ezetimibe-atorvastatin SPC approved in China; economic value assessment needed
The single-pill combination of ezetimibe and atorvastatin was approved in China in 2023 and added to the NRDL in 2024.
Therapeutic Area
Therapeutic area intelligence for Hypercholesterolemia with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.